Ivosidenib is an IDH1 inhibitor. It’s made for dealing with relapsed or hard-to-treat acute myeloid leukemia (AML) in people who have IDH1 mutations. It works by zeroing in on the faulty IDH1 enzyme to slow it down, which helps cut down on cancer cell growth.
Ivosidenib comes as 250 mg tablets with a coating. For adults, the suggested dose is 500 mg, once a day. That’s two tablets a day.
You take these tablets by mouth. Each bottle holds 60 tablets.
Reviews
There are no reviews yet.